Tumor Immunology & Immunotherapy
Program Leader: Eduardo Davila, Ph.D.
Clinical Leader: Aaron Rapoport, M.D.
The Tumor Immunology and Immunotherapy Program in the University of Maryland Marlene and Stewart Greenebaum
Cancer Center is dedicated to understanding the immune regulation of malignant
disease, and translating this knowledge into the development of novel diagnostic,
preventive, and treatment regimens. The program provides a forum to develop
interdisciplinary strategies that promote innovative research, create new therapeutic
options, and reduce the burden of cancer.
The principle scientific goals of the Tumor Immunology and Immunotherapy Program
are to develop, characterize, and apply immunological approaches for the prevention,
diagnosis, treatment, and monitoring of pre-malignant and malignant diseases
and disease progression. Importantly, these four themes are dynamic and interactive,
continually evolving to remain focused on clinical needs and translating programmatic
data for treatment and prevention strategies. The ability to achieve these goals
is enhanced by the interactive investigators with diverse expertise in clinical,
translational, and basic science.
This program has four scientific aims:
- To develop and characterize molecular and immunologic strategies for manipulating
the innate and adaptive immune responses to malignancy;
- To design and conduct preventive and therapeutic trials for selected cancers
utilizing the molecular immunological strategies identified in Aim 1;
- To develop an immunological monitoring program to be used in conjunction with
clinical outcomes to evaluate the efficacy of immunotherapy and conventional
- To provide an environment that facilitates and promotes collaborative interactions
between basic, translational, and clinical investigators, and to disseminate
knowledge and stimulate new ideas in cancer immunology.
This page was last updated: April 8, 2015